丹参酮IIA靶向Skp2克服结直肠癌化疗耐药

IF 5.9 2区 医学 Q2 CELL BIOLOGY
Xin Dong, Kexin Li, Ruirui Wang, Baojun Wei, Yiling Li, Yu Zhang, Shengkai Huang, Guojing Wang, Quanquan Gao, Wei Li, Wei Cui
{"title":"丹参酮IIA靶向Skp2克服结直肠癌化疗耐药","authors":"Xin Dong, Kexin Li, Ruirui Wang, Baojun Wei, Yiling Li, Yu Zhang, Shengkai Huang, Guojing Wang, Quanquan Gao, Wei Li, Wei Cui","doi":"10.1007/s10565-025-10084-w","DOIUrl":null,"url":null,"abstract":"<p><p>Fluorouracil (5-Fu)-based chemotherapy is a first-line treatment option for advanced colorectal cancer (CRC). However, long-term use of 5-Fu often leads to chemoresistance, which limits its therapeutic efficacy, highlighting the need for developing novel regimens to improve CRC treatment outcomes. In this study, we found that Tan IIA inhibits aerobic glycolysis in CRC cells via suppressing Skp2/Akt/HK2 signaling axis and thereby overcomes 5-Fu resistance. Specifically, Tan IIA induces ubiquitination-mediated Skp2 degradation by attenuating the interaction between USP2 and Skp2. Moreover, the combination of Tan IIA with USP2 inhibitor ML364 overcomes 5-Fu resistance in vitro and xenograft mouse models. This study elucidates a novel mechanism of 5-Fu resistance and offers a promising combination treatment option for overcoming chemoresistance.</p>","PeriodicalId":9672,"journal":{"name":"Cell Biology and Toxicology","volume":"41 1","pages":"135"},"PeriodicalIF":5.9000,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12500759/pdf/","citationCount":"0","resultStr":"{\"title\":\"Targeting Skp2 by Tanshinone IIA overcomes chemoresistance in colorectal cancer.\",\"authors\":\"Xin Dong, Kexin Li, Ruirui Wang, Baojun Wei, Yiling Li, Yu Zhang, Shengkai Huang, Guojing Wang, Quanquan Gao, Wei Li, Wei Cui\",\"doi\":\"10.1007/s10565-025-10084-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Fluorouracil (5-Fu)-based chemotherapy is a first-line treatment option for advanced colorectal cancer (CRC). However, long-term use of 5-Fu often leads to chemoresistance, which limits its therapeutic efficacy, highlighting the need for developing novel regimens to improve CRC treatment outcomes. In this study, we found that Tan IIA inhibits aerobic glycolysis in CRC cells via suppressing Skp2/Akt/HK2 signaling axis and thereby overcomes 5-Fu resistance. Specifically, Tan IIA induces ubiquitination-mediated Skp2 degradation by attenuating the interaction between USP2 and Skp2. Moreover, the combination of Tan IIA with USP2 inhibitor ML364 overcomes 5-Fu resistance in vitro and xenograft mouse models. This study elucidates a novel mechanism of 5-Fu resistance and offers a promising combination treatment option for overcoming chemoresistance.</p>\",\"PeriodicalId\":9672,\"journal\":{\"name\":\"Cell Biology and Toxicology\",\"volume\":\"41 1\",\"pages\":\"135\"},\"PeriodicalIF\":5.9000,\"publicationDate\":\"2025-10-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12500759/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell Biology and Toxicology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10565-025-10084-w\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Biology and Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10565-025-10084-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

氟尿嘧啶(5-Fu)化疗是晚期结直肠癌(CRC)的一线治疗选择。然而,长期使用5-Fu往往导致化疗耐药,这限制了其治疗效果,强调需要开发新的方案来改善结直肠癌的治疗结果。在本研究中,我们发现Tan IIA通过抑制Skp2/Akt/HK2信号轴抑制CRC细胞的有氧糖酵解,从而克服5-Fu耐药性。具体来说,Tan IIA通过减弱USP2和Skp2之间的相互作用,诱导泛素化介导的Skp2降解。此外,在体外和异种移植小鼠模型中,Tan IIA与USP2抑制剂ML364联合使用克服了5-Fu耐药性。该研究阐明了5-Fu耐药的新机制,并为克服化疗耐药提供了一个有希望的联合治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Targeting Skp2 by Tanshinone IIA overcomes chemoresistance in colorectal cancer.

Targeting Skp2 by Tanshinone IIA overcomes chemoresistance in colorectal cancer.

Targeting Skp2 by Tanshinone IIA overcomes chemoresistance in colorectal cancer.

Targeting Skp2 by Tanshinone IIA overcomes chemoresistance in colorectal cancer.

Fluorouracil (5-Fu)-based chemotherapy is a first-line treatment option for advanced colorectal cancer (CRC). However, long-term use of 5-Fu often leads to chemoresistance, which limits its therapeutic efficacy, highlighting the need for developing novel regimens to improve CRC treatment outcomes. In this study, we found that Tan IIA inhibits aerobic glycolysis in CRC cells via suppressing Skp2/Akt/HK2 signaling axis and thereby overcomes 5-Fu resistance. Specifically, Tan IIA induces ubiquitination-mediated Skp2 degradation by attenuating the interaction between USP2 and Skp2. Moreover, the combination of Tan IIA with USP2 inhibitor ML364 overcomes 5-Fu resistance in vitro and xenograft mouse models. This study elucidates a novel mechanism of 5-Fu resistance and offers a promising combination treatment option for overcoming chemoresistance.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cell Biology and Toxicology
Cell Biology and Toxicology 生物-毒理学
CiteScore
9.90
自引率
4.90%
发文量
101
审稿时长
>12 weeks
期刊介绍: Cell Biology and Toxicology (CBT) is an international journal focused on clinical and translational research with an emphasis on molecular and cell biology, genetic and epigenetic heterogeneity, drug discovery and development, and molecular pharmacology and toxicology. CBT has a disease-specific scope prioritizing publications on gene and protein-based regulation, intracellular signaling pathway dysfunction, cell type-specific function, and systems in biomedicine in drug discovery and development. CBT publishes original articles with outstanding, innovative and significant findings, important reviews on recent research advances and issues of high current interest, opinion articles of leading edge science, and rapid communication or reports, on molecular mechanisms and therapies in diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信